State lawmakers and regulators are grappling with how to balance the long-term potential and up-front cost of a blockbuster new class of drugs that promises to revolutionize obesity treatment.
Demand for glucagon-like peptide 1 agonists, or GLP-1 drugs, sold under brand names such as Wegovy, Ozempic and Monjaro has exploded in recent months, driven in part by celebrities and social media influencers.
Already a subscriber? Sign in